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Background: Thyroid dysfunction is a common complication of chronic hepatitis C (CHC) and its therapy.
Takotsubo cardiomyopathy (TCM) is a multifactorial, stress related cardiomyopathy, rarely reported in association
with thyrotoxicosis. Simultaneous occurrence of TCM and thyrotoxicosis due to hepatitis C and its treatment has
never been reported.
Case presentation: A 47-year-old woman was admitted for acute chest pain, dyspnea, palpitations and diaphoresis.
She had been diagnosed with CHC and had undergone 7 months of IFNα and Ribavirin therapy. At admission
electrocardiogram (ECG) showed ST segment elevation, negative T waves and troponin was elevated suggesting ST
segment elevation myocardial infarction (STEMI). Echocardiography demonstrated left ventricular apical akinesia and
ballooning, with a left ventricular ejection fraction (LVEF) of 35%. Contrast angiography showed normal epicardial
coronaries, yet a ventriculogram revealed left ventricular apical ballooning, consistent with TCM. Cardiac MRI
showed left ventricle apical ballooning and no late enhancement suggesting the absence of any edema, scar or
fibrosis in the left myocardium. She was diagnosed with non-autoimmune destructive thyroiditis: TSH=0.001 mU/L,
free T4=2.41 ng/dl, total T3=199 ng/dl and negative thyroid antibodies. The thyroid ultrasonography showed a
diffuse small goiter, no nodules and normal vascularization of the parenchyma. Following supportive treatment she
experienced a complete recovery after a few weeks and she successfully completed her antiviral treatment, with no
thyroid or cardiovascular dysfunction ever since. In patients treated with IFNα for CHC, the prevalence of thyroid
dysfunction varies between 2.5–45.3% of cases. TCM is a stress related cardiomyopathy characterized by elevated
cardiac enzymes, normal coronary angiography and an acute, transient, left ventricular apical dysfunction that
mimics myocardial infarction. Most of the patients survive the initial acute event, typically recover normal ventricular
function within one to four weeks and have a favorable outcome, as was the case with our patient. Thyrotoxicosis
induced stress cardiomyopathy is rare and has been mostly reported in association with Graves’ disease, thyroid
storm, thyrotoxicosis factitia or following radioiodine therapy for toxic multinodular goiter.
Conclusion: Routine thyroid screening should be done in patients receiving IFN-alpha and Ribavirin for CHC
and thyrotoxicosis should be considered as a possible and treatable underlying cause of TCM.
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Every year, 3–4 million people are infected with the
hepatitis C virus (HCV) and about 150 million people
are nowadays chronically infected worldwide [1]. Thyroid
dysfunction represents the most common endocrine mani-
festation of chronic hepatitis C (CHC). Combination the-
rapy with Interferon-alpha (IFNα) and Ribavirin represents
the standard treatment for CHC [2]. In patients treated
with IFNα for CHC, the prevalence of thyroid dysfunction
varies between 2.5–45.3% of cases [3], depending on the
study and diagnostic criteria applied. The main types of
interferon induced thyroiditis are: autoimmune thyroiditis
(Hashimoto’s thyroiditis, Graves’ disease or the devel-
opment of thyroid antibodies) and non-autoimmune
thyroiditis (destructive thyroiditis or non-autoimmune
hypothyroidism) [4]. Furthermore, thyroid dysfunction
is more prevalent in patients treated with IFN-α and
Ribavirin combination therapy (12.1%) than in patients
treated with IFN-α alone (6.6%) [5].
Takotsubo cardiomyopathy (TCM) is a multifactorial,
stress related cardiomyopathy characterized by elevated
cardiac enzymes, normal coronary angiography and an
acute, transient, left ventricular apical dysfunction that
mimics myocardial infarction. TCM caused by thyrotoxi-
cosis has previously been reported in about 12 cases
since 2004 [6].
We report a rare case of TCM associated with tran-
sient thyrotoxicosis, in a female patient treated with
IFN-α and Ribavirin for CHC, in order to highlight an
unusual complication of thyrotoxicosis and the difficul-
ties associated with the management of CHC.
Case presentation
In 2007, a 47- year- old Caucasian woman was admitted
for acute chest pain, dyspnea, palpitations and diaphoresis.
The symptoms had started 3 days prior to admission, after
experiencing emotional stress related to public lecture.
Metoprolol 100 mg/day had been started. The patient was
a nonsmoker and had no personal history of cardiovas-
cular disorders. She had been diagnosed with CHC in
2006 and had undergone 7 months of pegylate-IFN-
alpha (180 μg/week) and Ribavirin (1000 mg/day) ther-
apy. Physical examination on admission revealed a heart
rate of 85 beats/min and blood pressure of 160/80 mmHg.
Routine biochemical and hematological tests were normal,
except for the presence of anemia (hemoglobin = 9.74
g/dl, hematocrit = 31.4%), leucopenia (white blood cell
count = 4290/mm3, neutrophils = 2250/mm3), hypocho-
lesterolemia (123 mg/dl) and mild increase in liver en-
zymes (ALT = 53, AST = 55UI/L). C reactive protein was
negative. Plasma free metanephrines = 68 pg/ml (<90) and
normetanephrines = 126 pg/ml (<180) were in the normal
range. ECG at admission showed sinus rhythm 85 beats/
min, ST segment elevation and negative T waves in DI,DII, aVF, aVL, V2-V6 leads (Figure 1). The peak tro-
ponin was 2 ng/ml (<0.29). Echocardiography showed
normal cardiac cavities, left ventricular apical akinesia
and ballooning, septal hypokinesia and a LVEF of 35%
(Figure 2). Contrast angiography showed normal epi-
cardial coronaries (Figure 3), yet a ventriculogram re-
vealed left ventricular apical hypokinesis and ballooning,
consistent with TCM. For differential diagnosis and tissue
characterization, cardiac MRI was performed, showing
apical ballooning of the left ventricle. There were no
bright areas in T2 sequence with fat suppression and no
late enhancement suggesting the absence of any edema,
scar or fibrosis in the left myocardium (Figure 4).
During the first days the patient received supportive
therapy with angiotensin converting enzyme inhibitors,
beta-blockers (metoprolol 200 mg/day), platelet aggrega-
tion inhibitors, statin, low molecular weight heparin,
nitrates and anxiolytics, with favorable resolution of
dyspnea and no chest pain. The troponin returned rap-
idly to normal within 72 hours (0.044 ng/ml). Despite
high dose beta-blockers she was persistently tachycardic.
The endocrinological evaluation highlighted: patient
with no family or personal history of thyroid disorders,
without fever, pain in the cervical region or ophthalmo-
pathy; she had palpitations, excessive sweating, intoler-
ance to heat, nervousness, easy fatigability, hyperkinesia;
TSH = 0.001 mU/L, free T4 = 2.41 ng/dl (0.71-1.85), total
T3 = 199 ng/dl (81–178), anti-thyroid peroxidase anti-
bodies (TPOAb) = 3.8 IU/ml (0–12), antithyroglobulin
antibodies = 56 UI/ml (<115) and anti-thyrotropin recep-
tor antibodies (TRAb) = 1.05 IU/L (<1.75). The thyroid
ultrasonography showed a diffuse heterogenic small goi-
ter, no nodules and normal vascularization of the paren-
chyma. Non-autoimmune destructive thyroiditis was
diagnosed and the patient continued treatment with
beta-blockers and anxiolytics for the transient thyrotoxic
phase of the thyroiditis. Antiviral treatment for CHC
was stopped about 4 weeks and afterwards resumed,
with the same dosages, for another 11 month.
Dynamic ECG over the first 10 days revealed regression
and disappearance of the ST segment elevation, with per-
sistently negative T waves, which normalized 2 weeks
later. Repeat echocardiography performed 2 weeks after
the admission showed a normal LVEF, with apical hypoki-
nesia and 4 weeks later showed complete recovery of the
apical akinesia. The clinical picture with the absence of
late angina, the normalization of the ECG, associated with
normal epicardial coronaries at angiography and the tran-
sient, acute, left ventricular apical ballooning, enabled us
to diagnose a stress-related, reversible, ventricular apical
dysfunction.
In the next 3 months she developed transient hypo-
thyroidism and then became euthyroid (Figure 5). She
successfully completed her antiviral treatment and she
Figure 1 ECG at admission showing sinus rhythm 85 beats/min, ST segment elevation and negative T wave in DI, DII, aVF, aVL,
V2-V6 leads.
Figure 2 Baseline echocardiography showing normal cardiac cavities, septal hypokinesia, left ventricular apical akinesia
and ballooning.
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Figure 3 Right (A) and left (B) coronary arteriograms with normal coronary arteries without vasospastic phenomenon.
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roid function tests and cardiac echocardiography every
6 month, with no thyroid or cardiovascular dysfunction
ever since.
Discussion
TCM is an acute impairment of the cardiac function,
named after the Japanese fishing pot used for trapping
octopus, because of the peculiar left ventricle apical bal-
looning on left ventriculogram. The modified Mayo Clinic
criteria for the diagnosis of TCM are: 1) transient hy-
pokinesis, dyskinesis or akinesis of the left ventricularFigure 4 Cardiac MRI: 1,2 cine steady state free precession
(SSFP) in four chambers view with apical ballooning; 3,4 triple
inversion-recovery post injection of contrast agent with no late
enhancement in the left myocardium.midsegments, with or without apical involvement; the
regional wall-motion abnormalities extend beyond a
single epicardial vascular distribution, and a stressful
trigger is often, but not always, present; 2) absence of
obstructive coronary disease or angiographic evidence
of acute plaque rupture; 3) new electrocardiographic ab-
normalities (either ST-segment elevation and/or T-wave
inversion) or modest elevation in cardiac troponin level;
4) absence of pheochromocytoma or myocarditis [7].
Our case is a typical non-autoimmune destructive thy-
roiditis, in a woman with no personal history of thyroid
or cardiovascular disorders, but with known history of
CHC for which she was receiving IFNα and Ribavirin
therapy for 7 months prior to the diagnosis. A higher
prevalence of thyroid disorders has been reported in
HCV-infected patients than in the general population
[8]. Antiviral therapy of CHC possibly induces de novo
or exacerbates pre-existing silent thyroid disorders [9].
Thyroid diseases may occur anytime during therapy andFigure 5 Thyroid function tests in the first year following
the diagnosis.
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therapy. Furthermore, IFN-α dosage or treatment dur-
ation and the virological response to the treatment with
IFN-α and Ribavirin seem not to be related to the inci-
dence of thyroid dysfunction [10].
This case is special because of the unusual concomitant
association of two transient illnesses: IFN-α induced thy-
roiditis and acute left ventricular apical ballooning. The as-
sociation between thyrotoxicosis and cardiac complications
is well known, yet thyrotoxicosis induced stress cardio-
myopathy is rare [11]. TCM was reported in association
with varied thyroid functional status, ranging from se-
vere hypothyroidism [12], apathetic [13] or subclinical
hyperthyroidism [14], endogenous or exogenous thyro-
toxicosis [15,16], transient hyperthyroidism [17], thyroid
storm [11,18] to even normal thyroid function [19]. TCM
was also reported following radioiodine therapy [20] or
surgical treatment for thyroid disorders [21]. To the best
of our knowledge, until now, thyrotoxicosis induced stress
cardiomyopathy has never been reported in association
with thyroiditis precipitated by IFNα and Ribavirin ther-
apy for CHC.
The patient was initially admitted for symptoms sugges-
ting STEMI. However, echocardiography showing left
ventricle apical ballooning, correlated to the coronary
angiography that revealed no significant blockage and
the absence of late enhancement on cardiac MRI, en-
abled us to diagnose a stress related reversible ventricu-
lar apical dysfunction. Stress-induced cardiomyopathy is
an increasingly reported syndrome and it may account
for approximately 2% of suspected acute coronary syn-
dromes [22]. Left ventriculography is perhaps the best
imaging modality to demonstrate the pathognomonic
wall motion disturbance and to evaluate LVEF [23]. Cardiac
MRI is, also, an important diagnostic modality for TCM,
that can evaluate the regional wall motion abnormalities,
can quantify ventricular function and identify the presence
of edema/inflammation and the absence of necrosis/fibrosis
[24]. Furthermore, cardiac MRI can differentiate TCM,
characterized by the absence of delayed gadolinium hyper-
enhancement, from myocardial infarction and myocarditis,
in which the opposite occurs. Both left ventriculography
and cardiac MRI supported the TCM diagnosis in our case.
Yet, myocarditis could not be ruled out by immunohistolo-
gical examination of endomyocardial biopsies (EMB) or
virus PCR, as proposed by the fourth Mayo criteria. How-
ever, in the reported case series of TCM, endomyocardial
biopsy, the gold standard diagnostic for myocarditis, has
not been systematically performed [25]. In a recent re-
view, which included 286 patients from 14 studies, only
15 patients from 4 studies underwent EMB, with no evi-
dence of myocarditis in any of them [26].
Postulated mechanisms for TCM pathogenesis include:
direct cardiotoxicity of catecholamine excess, epicardialcoronary vasospasm, micro-vascular dysfunction, in situ
coronary thromboembolus with complete later recanaliza-
tion, shifts in cardiac metabolism from fatty acids towards
carbohydrates and left ventricular outflow tract obstruc-
tion, resulting in myocardial stunning [27]. Inflammation
and oxidative stress might also play a role [28].
75% of patients with TCM have elevated serum cat-
echolamine levels, even higher than patients with
STEMI [29], which may explain the hypothesis of vas-
cular dysfunction due to micro-vascular spasm. Supra-
physiologic levels of catecholamines could trigger a
switch in the coupling of β-2 adrenoreceptors from Gs to
Gi protein, leading to decreased contractility. The left ven-
tricular apex may be more vulnerable to catecholamine ex-
cess due to greater β-adrenergic receptor density and/or
increased myocardial responsiveness [30]. This catechol-
amine hypotesis is also supported by the rat models, where
Takostubo has been prevented with adrenergic blockade, by
sampling of cardiac catecholamine levels in TCM [31] and
by the reported cases in association with pheochromocy-
toma [32] and use of exogenous sympathomimetics.
The cause of myocardial stunning in thyrotoxic patients
with normal coronary arteries is still unknown. Thyroid
hormones have both direct and indirect actions on the car-
diovascular system, can alter cardiovascular hemodynamics
and represent a cause of cardiomyopathy. In thyrotoxic pa-
tients myocardial ischemia may occur due to coronary
vasospasm [33], in situ coronary thromboembolus or direct
metabolic effects of thyroid hormones.
The thyroid and adrenergic axes are closely interre-
lated, and pathologically high levels of thyroid hormones
cause exaggerated chronotropic and contractile re-
sponses to catecholamines. Thyroid hormones modulate
the transcription of multiple genes and also have extra-
nuclear actions in cardiac myocytes, leading to various
cardiovascular effects, similar to catecholamine-mediated
stimulation of β-adrenergic receptors [34]. Thyroid hor-
mones upregulate β-adrenergic receptors in many tissues,
including the heart [35], thus, increasing sensitivity to cat-
echolamines and potentiating catecholamine action. Fur-
thermore, experimental animal data have shown that
cardiovascular responses to hyperthyroidism are preserved
in mice lacking all three β adrenergic receptors compared
with wild-type mice [36]. An additional direct action of
thyroid hormones at the intracellular level has been sug-
gested based on the finding of thyroid hormone receptor
expression on cardiac myocytes [37]. Hyperthyroidism can
also mimic a state of catecholamine excess, mediated
through a change in the balance between sympathetic
and vagal innervation [38].
On the other hand, some studies have shown that plasma
catecholamine levels, as in our case, are usually normal in
TCM [6] and that the increase in β-adrenergic receptors is
not always accompanied by a corresponding increase in
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authors have even suggested that TCM might not be re-
lated to thyrotoxicosis, per se, but it could be a specific
complication of autoimmune thyrotoxicosis [41]. Yet, the
publication of TCM associated with exogenous thyrotoxi-
cosis and radioiodine-induced thyroiditis argues against this
theory.
Anyway, even if catecholamine levels are not increased in
hyperthyroidism, their action seems to be amplified resulting
in a hyper-responsive state to aminimal stimulation. Thyroid
hormones can induce a catecholamine-mediated cardio-
toxicity, which remains the most commonly proposed
mechanism in TCM.
Despite the potential severe presentation, most of the pa-
tients survive the initial acute event, typically recover nor-
mal ventricular function within one to four weeks and have
a favorable outcome, as was the case with our patient. Since
TCM usually progresses to a full recovery, the question
of whether patients with hyperthyroidism induced TCM
would have recovered even without the correction of the
thyroid function remains to be answered. Although infre-
quent, recurrence of the syndrome has been reported and
seems to depend on the nature of the trigger [42]. Our pa-
tient has been followed for nearly 5 and a half years, with
no recurrence of the TCM nor the thyroid dysfunction.
Conclusion
As previously suggested [4], we believe that TSH and thy-
roid antibody levels should be measured in all hepatitis
C patients prior to starting IFNα therapy and TSH levels
should be monitored every three months until completion
of IFNα course. In hepatitis C patients treated with IFNα,
multidisciplinary teams (gastroenterologist, endocrinologist,
cardiologist) should be aware that thyrotoxicosis could be a
possible and treatable underlying cause of TCM.
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